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ABSTRACT: Metformin, the first-line drug to treat type 2 diabetes (T2D), inhibits mitochondrial glycerolphosphate
dehydrogenase in the liver to suppress gluconeogenesis. However, the direct target and the underlyingmechanisms
by which metformin increases glucose uptake in peripheral tissues remain uncharacterized. Lipid phosphatase Src
homology 2 domain-containing inositol-5-phosphatase 2 (SHIP2) is upregulated in diabetic rodent models and
suppresses insulinsignalingbyreducingAktactivation, leading to insulin resistanceanddiminishedglucoseuptake.
Here, we demonstrate that metformin directly binds to and reduces the catalytic activity of the recombinant SHIP2
phosphatase domain in vitro.Metformin inhibits SHIP2 in cultured cells and in skeletalmuscle andkidney of db/db
mice. In SHIP2-overexpressingmyotubes,metformin ameliorates reduced glucose uptake by slowing down glucose
transporter 4 endocytosis. SHIP2 overexpression reducesAkt activity and enhances podocyte apoptosis, andboth are
restored to normal levels by metformin. SHIP2 activity is elevated in glomeruli of patients with T2D receiving
nonmetformin medication, but not in patients receiving metformin, compared with people without diabetes. Fur-
thermore, podocyte loss in kidneys of metformin-treated T2D patients is reduced compared with patients receiving
nonmetformin medication. Our data unravel a novel molecular mechanism by which metformin enhances glucose
uptake and acts renoprotectively by reducing SHIP2 activity.—Polianskyte-Prause, Z., Tolvanen, T. A., Lindfors, S.,
Dumont, V., Van,M.,Wang, H., Dash, S. N., Berg,M., Naams, J.-B., Hautala, L. C., Nisen, H.,Mirtti, T., Groop, P.-H.,
Wähälä,K.,Tienari, J., Lehtonen,S.Metformin increasesglucoseuptakeandacts renoprotectivelybyreducingSHIP2
activity. FASEB J. 33, 2858–2869 (2019). www.fasebj.org
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Metformin is recommended as a first-line therapy for type
2diabetes (T2D) (1).Metformin exerts itsglucose-lowering
effect by suppressing gluconeogenesis in the liver and fa-
cilitating glucose uptake and use by peripheral tissues (2,
3). Theproposedmechanismsof actionofmetformin in the
liver include inhibition of mitochondrial respiratory chain
complex I, regulation of gene transcription via peroxisome
proliferator-activated receptor g coactivator 1-a, and
modulation of the cellular redox state by inhibiting mito-
chondrial glycerolphosphate dehydrogenase (mtGPD),
leading to reduced gluconeogenesis (4–6). Metformin ac-
tivates energy sensor AMPK and inhibits its downstream
effector mammalian target of rapamycin, but it also acts
independently of AMPK (1, 7). It has been shown that
mtGPD is a direct target of metformin in the liver (6).
However, the direct molecular target and the exact mo-
lecularmechanismbywhichmetformin facilitates glucose
uptake in peripheral tissues have not been described.
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Decreased glucose uptake may result from suppressed
insulin signaling or impaired glucose transporter (GLUT)
4 trafficking. Insulin activates PI3K, which produces
phosphatidylinositol (3,4,5)-trisphosphate [PI(3,4,5)P3]
from phosphatidylinositol (4,5)-bisphosphate [PI(4,5)P2],
resulting in the activation of Akt, translocation of GLUT4
to the plasmamembrane (PM), and glucose uptake. Lipid
phosphatase Src homology 2 domain-containing inositol-
5-phosphatase 2 (SHIP2) suppresses PI3K-mediated in-
sulin signaling by hydrolyzing PI(3,4,5)P3 to PI(3,4)P2 (8).
SHIP2 is upregulated in adipose tissue, skeletal muscle,
and glomeruli of diabetic mice (9, 10). In humans, a mu-
tation in the UTR of inositol polyphosphate phosphatase-
like 1, the gene encoding SHIP2, associates with T2D, and
the expression of the mutant in vitro increases the ex-
pression of SHIP2 (11). SHIP2 knockoutmice are resistant
to high-fat diet-induced obesity (12), whereas mice over-
expressing SHIP2 have impaired glucose tolerance (13).
These data indicate that SHIP2 is a potential drug target to
treat insulin resistance. Insulin resistance is also a risk
factor for diabetic kidney disease (DKD) (14), which af-
fects 20–40%ofpatientswithdiabetes and is characterized
by loss of glomerular epithelial cells (podocytes) (15).
SHIP2 overexpression in podocytes reduces Akt activa-
tion and induces podocyte apoptosis (10), suggesting that
SHIP2 inhibition could also protect from podocyte loss.
Several SHIP2 inhibitors are known, but these are un-
favorable drug candidates as a result of their poor phar-
macokinetic properties and bioavailability (16). To discover
SHIP2 inhibitors with better drug-like properties, we per-
formed in silico structure-based virtual screening of small
molecule chemical libraries and identifiedmetformin. Here,
we demonstrate that metformin directly binds to and re-
duces the activity of the phosphatase domain of SHIP2,
providing a molecular mechanism by which metformin
enhancesglucoseuptakeandprotects againstpodocyte loss.
MATERIALS AND METHODS
In silico virtual screening
The active site of SHIP2 was determined using both the crystal
structure (3NR8)and the computationalmodel (O15357)of SHIP2
phosphatase domain. One cavity in both structures bound the
knownSHIP2 inhibitorAS1949490 (17) andPI(3,4,5)P3,matching
the site determined by Mills et al. (18). The High Throughput
BiomedicineUnit (UniversityofHelsinki,Finland) smallmolecule
libraries were used for in silico virtual screening by docking the
molecules to the active site of SHIP2 in both structures using
Discovery Studio 4.0 (Biovia, San Diego, CA, USA).
Cell culture and biochemical assays
Rat L6myoblasts (American TypeCultureCollection,Manassas,
VA, USA) and hepatoma cells (Fao Cells, Culture Collection;
Public Health England, Salisbury, United Kingdom) were
maintained according to the provider’s instructions. L6 myo-
blasts stably expressing hemagglutinin-GLUT4-green fluores-
cent protein (HA-GLUT4-GFP, referred to as L6-GLUT4) were
generated, as previously described (19). Immortalized human
podocytes were maintained as previously described (10). Lenti-
viral infection was used to overexpress or knock down tran-
siently SHIP2 in cultured cells on d 10–12 of differentiation for
48 h (basal level) or 72 h (insulin stimulation), as previously de-
scribed (10, 20). Human pLKO1-short hairpin RNA (shRNA)
SHIP2 (CCACCCAAGAACAGCTTCAAT) was obtained from
Functional Genomics Unit, University of Helsinki. Apoptosis was
measuredby flowcytometryusing theAnnexinV-FITCApoptosis
Kit (Becton Dickinson, Franklin Lakes, NJ, USA) and double
staining with 7-aminoactinomycin D (Becton Dickinson), as pre-
viously described (10). Podocytes were lysed as previously de-
scribed (21).Myotubes, hepatoma cells, and tissueswere lysed and
immunoblotting performed as in Tolvanen et al. (19) with anti-
SHIP2 and anti-AMPK (Santa Cruz Biotechnology, Dallas, TX,
USA); anti-phospho (p)Akt (S473), anti-pAMPK (Thr172), anti-
AMPK, and anti-cleaved caspase-3 (Cell Signaling Technology,
Danvers, MA, USA); anti-Pan Akt (R&D Systems, Minneapolis,
MN, USA); anti-tubulin, anti-Glut4, and anti-Glut1 (Millipore-
Sigma, Burlington, MA, USA); and anti-actin (Abcam, Cam-
bridge, United Kingdom). Immunofluorescence and cell-surface
labeling with anti-HA.11 (Covance, Princeton, NJ, USA) were
performed as in Tolvanen et al. (19) andHeikkila et al. (21) using
CAS-Block (Vector Laboratories, Burlingame, CA, USA).
Production of recombinant SHIP2 and
SHIP1 phosphatase domains and
SHIP2 immunoprecipitation
RecombinantHis-tagged human SHIP2 and SHIP1 phosphatase
domains were produced as previously described (17). Lysates
from myotubes, podocytes, and hepatoma cells, treated with
metformin (MilliporeSigma) at indicated concentrations for
20–24 h or from tissues of mice treated with metformin for 12 d,
were precleared with protein G-Sepharose (Thermo Fisher Sci-
entific, Waltham, MA, USA) at +4°C for 1 h and incubated with
anti-SHIP2 or goat IgGs for 16–20 h at +4°C. Immunocomplexes
were bound to protein G-Sepharose beads at +4°C for 2 h
and washed 3 times with malachite green phosphate assay
buffer {10mM4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), pH 7.25, 6 mM MgCl2, 0.1% 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS), 250 mM
sucrose, and 0.25 mM EDTA}.
SHIP2 activity measurement
The catalytic activities of the recombinant SHIP2 and SHIP1
phosphatase domains were determined by malachite green
phosphate assay at the High Throughput Biomedicine Unit
(University of Helsinki) using D-myo-PI(3,4,5)P3 (Echelon Bio-
sciences, Salt Lake City, UT, USA). Different volumes, resulting
in desired final concentrations of inhibitors, were transferred
to the wells of 384-well plates by using the Echo550 acoustic
dispenser (Labcyte, San Jose, CA, USA). Recombinant protein
(100ng) in reaction buffer {10mMHEPES, pH7.25, 6mMMgCl2,
0.1% CHAPS, 250mM sucrose, and 0.25mMEDTA}was placed
in each well (7.5 ml), and the plates were preincubated at room
temperature for 15min. The phosphatase reactionwas started by
adding PI(3,4,5)P3 diluted in the reaction buffer (7.5 ml) to each
well to reach a final concentration of 100 mM PI(3,4,5)P3 in the
15 ml reaction volume. The plates were incubated at room tem-
perature for 20 min, after which, 15 ml BIOMOL green reagent
(Biomol, Plymouth Meeting, PA, USA) was added to each well,
and then the plates were incubated for another 25 min at room
temperature. Absorbance was measured at 620 nm using a
Pherastar FS plate reader (BMG Labtech, Offenburg, Germany).
For themanualmalachitegreenphosphateassay in96-wellplates
[see Fig. 1; and activity measurement of phosphatase and tensin
homolog (PTEN; Signalchem, Richmond, BC, Canada)], the re-
action volume was increased to 50 ml, and 100 ml Biomol Green
Reagent was added. The catalytic activity of SHIP2 immuno-
precipitated from cell and tissue lysates was determined as in
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Saurus et al. (22), omitting SHIP2 inhibitors in lysis buffer, im-
munoprecipitation reaction, wash, and assay buffers. AS1949490
was synthesized, as described in Supplemental Fig. S1A, or
purchased from Tocris Bioscience (Bristol, United Kingdom).
Glucose uptake and GLUT4 translocation assays
Glucose uptake assay and On-Cell Western were performed es-
sentially as in Tolvanen et al. (19). For HA-GLUT4-GFP endocy-
tosis assay, L6-GLUT4 cells were incubated under basal
conditions with metformin (2 mM, 20–24 h) or stimulated with
insulin (100 nM, 15min). Cellswere transferred on ice; incubated
with anti-HA IgG in serum-freemedium for 15min, followed by
additional incubation in fresh cell differentiation medium for 15
min at +37°C; and fixed with 2% paraformaldehyde for 20 min.
Cells were incubated with IRDye 800 donkey anti-mouse IgG
and nuclear marker DRAQ-5 (Thermo Fisher Scientific). De-
tection and quantitation were performed with the Odyssey In-
frared Imager (Li-Cor Biosciences, Lincoln, NE, USA).
Metabolic assays in db/db mice
Male C57BL/Ks-db/db (BKS.Cg-m+/+Lepr) mice (Scanbur,
Karlslunde, Denmark) were maintained according to the prin-
ciples of laboratory animal care, and the experiments were ap-
proved by the National Animal Experiment Board. db/db mice
(8 wk) were randomly divided into metformin and control
groups (n = 7–8/group). Metformin (MilliporeSigma) was ad-
ministered in drinking water (250 mg/kg/d) for 12 d, with the
final dose administered by gavage, 4 h before euthanasia. Blood
glucose concentrations and insulin tolerance test (after 12 d
of metformin treatment), using human insulin (0.75 U/kg;
Actrapid, Novo Nordisk, Denmark), were performed with Bay-
er’s Elite Glucometer after 6 h fasting. Urine (24 h) was collected
individually in metabolic cages, and total urinary albumin con-
tent was measured at the Biochemical Analysis Core for Experi-
mental Research (University of Helsinki). At the end of the
experiment, mice were euthanized. Freshly dissected skeletal
muscle, kidney, and liver tissues were snap frozen in liquid ni-
trogen, embedded in Tissue-Tek Optimal Cutting Temperature
(OCT) compound (Sakura Finetek, Alphen aan den Rijn, The
Netherlands), or fixed in 10% formalin, followed by embedding
in paraffin. Quantitative RT-PCRwas performed as in Dash et al.
(23). The primers used to amplify phosphoenolpyruvate car-
boxykinase 1 (PCK1) were the following: forward 59-CCAAG-
AGCAGAGAGACACAG-39 and reverse 59-CAATACCAATC-
TTGGCCAGC-39 and glucose-6-phosphatase (G6Pase) forward
59-CATCAATCTCCTCTGGGTGG-39 and reverse 59-TGCTGT-
AGTAGTCGGTGTCC-39. Values were normalized to actin,
amplified with primers forward 59-GTTCGCCATGGATGAC-
GATA-39 and reverse 59-ACATAGGAGTCCTTCTGACC-39, or
18S RNA, amplified with primers forward 59-GAGGGACAA-
GTGGCGTTCAG-39 and reverse 59-ATCACGAATGGGGTT-
CAACG-39.
Immunohistochemical analysis
Kidney samples of renal cancer patients, with or without di-
abetes, representing nonmalignant part of the kidney, were
obtained from surgical nephrectomies performed at theHelsinki
and Uusimaa Hospital district. Patient characteristics are de-
scribed inSupplementalTableS1.Theuseofhumanmaterialwas
approved by the local Ethics Committee, and written, informed
consent was received from study participants. Paraffin sections
were stained with anti-SHIP2 (I-20) as in Hyvonen et al. (10) or
anti- Wilms tumor protein 1 (WT1; Santa Cruz Biotechnology)
using the Brightvision Poly-HRP-anti-Rabbit IgG kit
(ImmunoLogic, Amsterdam, The Netherlands) and 3,39-dia-
minobenzidine (Dako Cytomation, Carpinteria, CA, USA).
Slides were counterstained with hematoxylin and digitally
scanned with 3DHistech Pannoramic 250 FLASH II (3DHis-
tech, Budapest, Hungary) at the Genome Biology Unit (Uni-
versity of Helsinki). Quantification of SHIP2 staining intensity
was performed with the HistoQuant module (3DHistech).
Podocyte number was estimated by counting the number of
WT1-positive cells per glomerular cross-section in 10 glo-
meruli per patient in a blinded manner, as described in Guo
et al. (24). Only glomeruli larger than 170mm in diameter were
examined to ensure sectioning through the center of each
glomerulus.
Statistical analyses
Data are shown as means 6 SD or SEM. Statistical analyses were
performed using a 2-tailed Student’s t test or 1-way ANOVA
with Bonferroni adjustment. Values of P# 0.05 were considered
as statistically significant.
RESULTS
Identification of novel SHIP2 inhibitors
To identify novel SHIP2 inhibitors in silico, we performed
structure-based virtual screening of small molecule li-
braries by virtually docking the molecules to the catalyti-
cally active site of SHIP2 in both the crystal structure and
the computational model of SHIP2 phosphatase domain.
Screening of 88,640 molecules revealed 2636 molecules
that bound to both SHIP2 structures. A total of 379 mole-
cules had more favorable interaction energies than the
previously characterized SHIP2 inhibitor AS1949490 and
were selected for biologic validation. For this, we pro-
duced a His-tagged human SHIP2 phosphatase domain
and tested the potency of the compounds to inhibit its
catalytic activity by malachite green phosphate assay.
Four compounds had half-maximal inhibitory concentra-
tion (IC50) values lower than 10 mM (Supplemental Table
S2 andTable 1), and one of themwasmetformin (Fig. 1A).
Metformin inhibits SHIP2
Metformin reduces the catalytic activity of the recombi-
nant SHIP2 phosphatase domain by 44% (Fig. 1B) with an
IC50 value of 6 mM (Supplemental Fig. S1B). Metformin
does not inhibit SHIP1, 38% homologous with SHIP2, or
PTEN, a lipid 39-phosphatase (Table 1). AS1949490 re-
duced the activity of the recombinant SHIP2 and SHIP1
phosphatase domains by 26 and 12%, respectively (Table
1). Enrichment of SHIP2 by immunoprecipitation from
cultured cells and measurement of the phosphatase ac-
tivity in the precipitate revealed that 1 mM metformin
reduces SHIP2 activity by 24% in myotubes and 14% in
podocytes (Fig. 1C, D) but not in hepatoma cells (Supple-
mentalFig. S2A).AS1949490 (10mM)didnot inhibit SHIP2
in hepatoma cells either (Supplemental Fig. S2A). Low,
20 mM concentration of both metformin and AS1949490
reducedSHIP2 activity by;30%inmyotubes and20–30%
in podocytes (Fig. 1E, F). Metformin treatment had no
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effect on SHIP2 expression level in cultured cells (Sup-
plemental Fig. S3A–D, I, O). These data indicate that
metformin selectively and efficiently reduces SHIP2 ac-
tivity in myotubes and podocytes.
Metformin enhances glucose uptake into cells
by inhibiting SHIP2 activity
Insulin increased glucose uptake in L6-GLUT4 cells
(Supplemental Fig. S4A, B) by 20% and metformin by
218%, but metformin, together with insulin, did not have
an additive effect (Fig. 2A). Immortalized human podo-
cytes, cultured inmediumsupplementedwith insulin, did
not respond to insulin by increasing glucose uptake, but
metformin increased glucose uptake by 52%, and metfor-
min, together with insulin, further potentiated the effect
leading to an 80% increase in glucose uptake (Fig. 2B).
To confirm that metformin increases glucose uptake
by inhibiting SHIP2, we performed SHIP2 knockdown
and overexpression experiments, both expected to re-
duce metformin-induced glucose uptake. Reduction of
TABLE 1. IC50 values and inhibition efficiencies of SHIP2 inhibitors identified in the virtual screening and their specificity for SHIP2 in relation





efficiency (%) IC50 (mM)
Inhibition
efficiency (%) IC50 (mM)
Inhibition
efficiency (%)
Metformin 6.0 39.4 .50 11.1 .50 0
Megestrol acetate 6.2 76.6 24.6 30 N/T N/T
Mercaptopurine 8.8 52.9 21.2 11.4 N/T N/T
Thioguanine 9 44.9 .50 29.9 N/T N/T
AS1949490 N/A 25.9 .50 11.8 .50 0
Inhibition efficiencies were determined using the inhibitors at 100 mM concentration. The measurements for SHIP2 and SHIP1 purified His-
tagged phosphatase domains were carried out in the High Throughput Biomedicine Unit. N/A, not applicable; N/T, not tested.
Figure 1. Metformin reduces the catalytic activity of SHIP2. A) Predicted binding orientation of metformin to the active site of SHIP2.
Hydrogen bond is shown in green. Hydrophobic residues are shown in gray, positive-charged residues in blue, and negative-charged
residues in red. B) Metformin (10 mM) reduces the activity of purified His-tagged SHIP2 phosphatase domain (100 ng). C, D)
Metformin (1 mM, 20–24 h) reduces the activity of SHIP2 immunoprecipitated from the lysates of L6 myotubes (C) and podocytes
(D). E, F) Metformin and AS1949490 at 20 mM concentration (20–24 h) reduce the activity of SHIP2 immunoprecipitated from the
lysates of L6 myotubes (E) and podocytes (F). The catalytic activity of SHIP2 was measured by manual malachite green phosphate
assay. Data are presented as the mean 6 SD of 3–5 independent experiments . **P # 0.01, ***P # 0.001 (Student’s t test).
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SHIP2 expression in L6-GLUT4 myotubes by 30–
45% (Supplemental Fig. S5A, B) increased insulin-
stimulated glucose uptake by 9% (Fig. 2C), confirming
previously reported weak or no effects of SHIP2
knockout/knockdown on insulin signaling/sensitivity
and glucose uptake (12, 25). Metformin enhanced glu-
cose uptake by 148% in L6-GLUT4 myotubes, whereas
metformin coupled to SHIP2 knockdown increased
insulin-stimulated glucose uptake by only 109% (Fig.
2C), indicating that reduced expression of SHIP2 de-
creases the ability of metformin to enhance glucose
uptake.
SHIP2 overexpression in myotubes led to an average
30–45% increase in SHIP2 expression (Supplemental Fig.
S5C, D) and 50% increase in SHIP2 activity (Fig. 2D).
Metformin decreased the SHIP2 overexpression-induced
SHIP2 activity to the level in the control (Fig. 2D), and the
amounts of immunoprecipitated SHIP2 used for activity
Figure 2. Knockdown and overexpression of SHIP2 decrease metformin-induced glucose uptake, and metformin slows down the
endocytosis of GLUT4. A, B) Metformin increases glucose uptake in myotubes and podocytes. Serum-starved L6-GLUT4 myotubes
(A) and podocytes (B), which were additionally starved of insulin-transferrin-selenium for 72 h, were treated with metformin (2 mM;
20–24 h) and/or stimulated with insulin (100 or 200 nM, respectively; 15 min), followed by glucose uptake assay. C) Knockdown of
SHIP2 reduces metformin-induced glucose uptake. L6-GLUT4 myotubes were infected with SHIP2 or control shRNAs, treated with
metformin (2 mM, 20–24 h) under insulin (100 nM, 15 min)-stimulated conditions, followed by glucose uptake assay. D) SHIP2
overexpression increases SHIP2 activity, and metformin restores it back to the level of the control. L6 myotubes overexpressing
SHIP2 or empty vector (control) were incubated with metformin (1 mM; 20–24 h), and the phosphatase activity of im-
munoprecipitated SHIP2 was measured by malachite green phosphate assay. E) SHIP2 overexpression abrogates the effect of
metformin to induce glucose uptake. L6-GLUT4 myotubes overexpressing SHIP2 were treated and glucose uptake performed as
described in C. F) AICAR (1 mM; 20–24 h), alone or together with insulin (200 nM, 15 min), does not increase glucose uptake in
podocytes. G) Quantification of the On-Cell Western signal for HA revealed that metformin increases the HA-GLUT4-GFP level at
the PM. L6-GLUT4 myotubes were incubated under basal conditions and treated with metformin (2 mM; 20–24 h), followed by On-
Cell Western assay. H) Metformin slows down endocytosis of HA-GLUT4-GFP in L6-GLUT4 cells. Time point 0 min indicates the
amount of HA on the cell surface after metformin (2 mM; 20–24 h) or insulin (100 nM; 15 min) treatment and is set to value 1.
Time point 15 min indicates the amount of HA detected on the cells after 15 min internalization. Data are presented as the mean6
SD of 3–4 independent experiments. *P # 0.05, **P # 0.01, ***P # 0.001 (Student’s t test).
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measurements showed no difference between the sam-
ples confirming equal input (Supplemental Fig. S5E). In
L6-GLUT4 myotubes, SHIP2 overexpression decreased
insulin-stimulated glucose uptake by 20–25% (Fig. 2E).
Metformin increased glucose uptake by 155% in empty
vector-transfectedmyotubes,whereasmetformin coupled
to SHIP2 overexpression increased insulin-stimulated
glucose uptake by only 76% (Fig. 2E), indicating that
SHIP2 overexpression abrogates the ability of metformin
to enhance glucose uptake. Collectively, these data sug-
gest that metformin enhances glucose uptake by reducing
SHIP2 activity.
Metformin slows down endocytosis of GLUT4
SHIP2 overexpression reduces insulin-induced Akt activ-
ity (10, 13), and metformin activates AMPK (26). Metfor-
min did not increase Akt phosphorylation (activity) in
myotubes and podocytes in basal state (Supplemental Fig.
S3A, B, G, L) but increased AMPK phosphorylation (ac-
tivity) 2- to 3-fold (Supplemental Fig. 3A–C, H, M, P).
A well-established pharmacological activator of AMPK,
5-aminoimidazole-4-carboxamide ribonucleoside (AICAR),
increased AMPK activity 2-fold in podocytes (Supple-
mental Fig. S3B, N), but in contrast to myotubes (27),
AICAR or insulin combined with AICAR failed to in-
crease glucoseuptake inpodocytes (Fig. 2F). This suggests
that AMPK activation might only partly account for the
action of metformin on glucose uptake or that there may
be cell type-specific differences in the action ofmetformin.
Metformin has been shown to increase glucose uptake
in peripheral tissues by regulating GLUT trafficking (28,
29). Indeed, metformin increased the amount of HA-
GLUT4-GFP on the PM by 40% in L6-GLUT4 cells (Fig.
2G). A 15 min HA-GLUT4-GFP uptake assay, defining
endocytosis of HA-GLUT4-GFP, revealed only a 10% de-
crease in the amount of HA-GLUT4-GFP on the PM in
metformin-treatedmyotubes contrary to a20%decrease in
cells at basal state or treated with insulin (Fig. 2H). Met-
formin had no effect on GLUT1 and GLUT4 protein ex-
pression levels inmyotubes andpodocytes (Supplemental
Fig. S3A, B, E, F, J, K). Collectively, these data show that
metformin slows down GLUT4 endocytosis without af-
fecting its expression level.
Metformin prevents SHIP2 overexpression-
induced apoptosis in cultured podocytes
SHIP2 overexpression induces podocyte insulin resistance
and apoptosis (10). SHIP2 overexpression, by 50–60% in
podocytes (Fig. 3A, B), increased podocyte apoptosis, as
visualized by an increase in the cleavage of caspase-3,
whereas metformin reduced the cleaved caspase-3 level
back to the level in the control (Fig. 3A,C). Thiswas further
confirmed by Annexin V staining and flow cytometry
analysis, showing that SHIP2 overexpression increased
the level of apoptotic cells, and metformin decreased the
level of apoptosis back to the level of the control (Fig. 3D,
E). SHIP2 overexpression decreased the insulin-induced
Akt phosphorylation in podocytes by 35%, whereas
metformin restored its activity (Fig. 3F, G). These data
show that metformin protects podocytes against SHIP2
overexpression-induced apoptosis by re-establishing the
activity of the Akt cell-survival pathway.
Metformin inhibits the catalytic activity of
SHIP2 in muscle and kidney of db/db mice
To confirm that metformin targets SHIP2 in vivo, we ad-
ministered metformin daily to diabetic db/dbmice at 250
mg/kg per day, which when normalized to body-surface
area, translates to a human metformin dose of 20 mg/kg
per day (1).Metformin treatment decreased the enzymatic
activity of SHIP2 by 40% in the skeletalmuscle and kidney
(Fig. 4A, B) without affecting SHIP2 expression level
(Supplemental Fig. S6A–D, I,N). SHIP2 activity in the liver
was not reduced by metformin (Supplemental Fig. S2B).
Metformin did not activate Akt or AMPK (Supplemental
Fig. S6A–C, G,H, L,M,O) or increase the expression levels
of GLUT1 and GLUT4 in skeletal muscle or kidney (Sup-
plemental Fig. S6A, B, E, F, J, K). Metformin had no effect
on body weight, urinary albumin excretion, or fasting
blood glucose concentrations compared with nontreated
db/db mice (Fig. 4C–E). Insulin tolerance test, assessing
whole-body glucosemetabolism, revealed thatmetformin
reduces fasting blood glucose at 30–120 min after insulin
administration and the glucose area under the curve,
whereas the blood glucose concentrations were un-
changed in the nontreated db/db mice (Fig. 4F, G). In
addition, metformin decreased the mRNA levels of the
key gluconeogenesis genes, PCK1 and G6Pase, in liver of
db/db mice (Supplemental Fig. S2C, D), confirming the
effectiveness of our 12 d treatment. In contrast to this, met-
formin increased the mRNA levels of PCK1 and G6Pase in
kidney of db/db mice (Supplemental Fig. S2E, F). These
data collectively indicate that metformin reduces the
activity of SHIP2 in skeletal muscle and kidney cells
both in vitro and in vivo and enhances insulin sensitivity
in db/db mice.
The catalytic activity of SHIP2 and podocyte
loss are decreased in kidneys of human
patients with T2D receiving metformin
In humans, SHIP2 activity was 39% higher in the kidneys
of patients with T2D without clinical nephropathy and
who received nonmetformin medication (insulin or sul-
fonylurea), whereas the SHIP2 activity in the kidneys of
patients with T2D receiving metformin was similar to
that in peoplewithout diabetes (Fig. 5A andSupplemental
Table S1). SHIP2 expression level showed no difference
in glomeruli and kidney cortex between the groups
(Fig. 5B–D). The number of podocytes per glomeruli was
decreased by 38% in patients with T2D with non-
metformin medication, whereas metformin-receiving pa-
tients showed only 11% podocyte loss compared with
people without T2D (Fig. 5E, F). These data on patient
kidneysamples suggest thatmetforminreduces thecatalytic
activity of SHIP2 and protects against podocyte loss. This,
together with the data on cultured cells and db/db mice,
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proposes that inhibition of SHIP2 bymetformin could be an
important mechanism to increase glucose uptake into cells
and ameliorate kidney injury in patients with T2D.
DISCUSSION
We performed structure-based virtual screening to iden-
tify new, SHIP2-specific inhibitors, and a highlight of the
screening was the identification of the anti-diabetic drug
metformin. Studies haveproposedvariousmechanismsof
action formetformin to reducegluconeogenesis in the liver
(5) orviaaffecting thegutmicrobiota (30), reportingmainly
indirect effects of metformin through various pathways
involved in themetabolic control. Thus far, onlyMadiraju
et al. (6) and this study have revealed tissue-specific, direct
cellular targets of metformin, mtGPD in liver, and SHIP2
in muscle and kidney, contributing to the effect of met-
formin to reduce gluconeogenesis and increase glucose
uptake, respectively.
We observed that both metformin and AS1949490 re-
duce theenzymatic activityof SHIP2 in culturedmyotubes
Figure 3. Metformin restores prosurvival Akt signaling and protects podocytes from SHIP2 overexpression-induced apoptosis. A)
SHIP2 overexpression increases the expression of cleaved caspase-3 in podocytes, and metformin (2 mM, 48 h) restores it back to
the level in the control (empty vector). Cell lysates were subjected to immunoblot analysis with anti-SHIP2, anti-cleaved caspase-3,
and anti-actin IgGs. Representative protein bands are from the same immunoblot. B, C) Quantification of SHIP2 and cleaved
caspase-3 levels in A, normalized to actin. D) SHIP2 overexpression increases the proportion of apoptotic cells in podocytes, and
metformin (2 mM, 48 h) restores it back to the level in the control (empty vector). Apoptosis was measured by flow cytometry
using Annexin V-FITC and 7-aminoactinomycin D (7AAD) double staining. E) Representative images of 5 independent
experiments, each with 3 replicates, showing flow cytometry analysis of control (empty vector) or SHIP2-overexpressing
podocytes treated or not with metformin. F) SHIP2 overexpression decreases insulin-induced pAkt in podocytes, and metformin
restores it back to the level in the control (empty vector). Podocytes overexpressing SHIP2 or empty vector (control) were
incubated with metformin (2 mM; 20–24 h) and stimulated with insulin (200 nM; 15 min). Cell lysates were subjected to
immunoblot analysis with anti-SHIP2, anti-Akt, anti-pAkt, and anti-actin IgGs. G) Quantification of pAkt levels in F presented as
pAkt/Akt after normalizing to actin. Data are presented as the mean 6 SD of 3–5 independent experiments. *P # 0.05, **P #
0.01, ***P # 0.001 (Student’s t test).
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and podocytes but not in hepatoma cells. Also in vivo in
db/db mice, metformin inhibited SHIP2 in the skeletal
muscle and kidney but not in the liver, even though the
expression of the rate-limiting enzymes of gluconeo-
genesis was reduced. This suggests that metformin does
not suppress gluconeogenesis via SHIP2 inhibition in
liver. Previously, SHIP2 inhibitors AS1949490 and N-[4-
(4-chlorobenzyloxy)pyridin-2-yl]-2-(2,6-difluorophenyl)-
acetamide were also found to reduce PCK1 expression in
db/db mice (31). However, the authors did not measure
whether SHIP2 activity in the liver was reduced by the
treatments, leavingopenwhether the effectwas a result of
direct inhibition of SHIP2 or occurred indirectly via an-
other target. The reason why metformin does not inhibit
SHIP2 in the liver is unclear. It is possible that there
are certain organ-specific mechanisms that determine to
which target protein metformin binds. For example, the
interaction partners of SHIP2 andmtGPD and the protein
complexes formed thereby may affect the binding of
metformin. This remains to be analyzed in future studies.
We (10) and others (9) previously showed that SHIP2 is
upregulated in various tissues in rodent models of T2D.
However, SHIP2 activity may be enhanced in diabetes
without an increase in its expression level, aswasobserved
in the kidneys of patients with T2D. Furthermore, de-
creased SHIP2 activity after metformin treatment was not
a result of reduced expression of SHIP2. Collectively, our
in vitro and in vivo data indicate that metformin acts on
SHIP2 by reducing its activity, without an influence on its
expression level.
Metformin enhances glucose uptake into cells (27, 32).
We show that this occurs by reducing SHIP2 activity, as
Figure 4. Metformin decreases the catalytic activity of SHIP2 in db/db mice. A, B) Metformin decreases the catalytic activity of
SHIP2 in skeletal muscle (A) and kidney (B) of db/db mice. SHIP2 was immunoprecipitated from tissue lysates and its catalytic
activity measured by malachite green phosphate assay (n = 6–8). C–E) Twelve d metformin treatment has no effect on body
weight (C), urinary albumin excretion (D), and fasting blood glucose (E) in db/db mice (n = 7–8). F, G) Metformin improves
insulin sensitivity of db/db mice. Insulin tolerance test was performed and blood glucose measured at the indicated times after
insulin injection, and the area under the curve (AUC) was calculated (n = 5–6). Data are presented as the mean6 SEM. *P# 0.05,
**P # 0.01 (Student’s t test).
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Figure 5. SHIP2 activity and podocyte loss are reduced in kidneys of human patients with T2D receiving metformin. A) SHIP2 activity is
increased in kidneys of patients with T2D receiving nonmetformin medication compared with people without T2D. SHIP2 activity in
patients with T2D receiving metformin medication is similar to people without T2D. Kidney samples were lysed, and the enzymatic
activity of immunoprecipitated SHIP2 was analyzed by malachite green phosphate assay (n = 4–7). B) SHIP2 expression level in glomeruli
in D was quantified with the HistoQuant (3DHistech) program. Ten randomly chosen glomeruli were analyzed from each patient (n =
6–7). C) SHIP2 expression level in kidney cortex was quantified with 3DHistech (n = 5–7). D) SHIP2 staining in human glomeruli of
patients with T2D receiving metformin or nonmetformin medication and people without T2D. Paraffin sections of nephrectomy samples
were processed for immunoperoxidase staining and labeled with anti-SHIP2 IgG. E) WT1 staining in human glomeruli of patients with
T2D receiving metformin or nonmetformin medication and people without T2D. Paraffin sections of nephrectomy samples were
processed for immunoperoxidase staining and labeled with anti-WT1 IgG. F) Podocyte loss is decreased in kidneys of patients with T2D
receiving metformin medication compared with patients receiving nonmetformin medication. Podocyte number per glomeruli was
quantified by counting WT1-positive cells. Ten randomly chosen glomeruli were analyzed from each patient (n = 9–30). Original scale
bars, 50 mm. Data are presented as means 6 SEM. *P # 0.05, **P # 0.01, ***P # 0.001; ANOVA (B–F); Student’s t test (A).
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knockdownand overexpression of SHIP2 decreased the
ability of metformin to induce glucose uptake in myo-
tubes. In line with this, we observed that metformin
improves insulin sensitivity in db/db mice, supporting
the potential of SHIP2 as a target to improve glucose
metabolism. Involvement of SHIP2 in glucose metabo-
lism is further supported by a similar short-term
AS1949490 treatment, which reduced blood glucose
and improved insulin sensitivity in db/db mice (17). In
line with previous literature (33, 34), we observed no
difference in body weight, albuminuria, or fasting
blood glucose in db/db mice after short-term metfor-
min treatment. The latter could be explained by our
finding that the renal expression of PCK1 and G6Pase
was increased after metformin treatment, apparently
enhancing gluconeogenesis in the kidney cortex, com-
pensating for the reduced hepatic glucose production.
This accords with the role of the kidney in gluconeo-
genesis (35) and is supported by a previous study re-
vealing that 10 wk metformin treatment of db/db mice
exacerbates the diabetes-induced increase in the ex-
pression of gluconeogenic genes in the kidney (34). The
regulation of gluconeogenesis bymetformin is complex
(5). In the liver, metformin apparently does not inhibit
gluconeogenic gene expression directly at the transcrip-
tional level but inhibits gluconeogenesis via decreasing
the hepatic energy state by reducing intracellular ATP
content (36) or affecting the cellular redox state (6). The
exactmolecularmechanism viawhich SHIP2 inhibition in
the kidney or as a compensatory response to reduced
hepatic gluconeogenesis leads to an increase in renal
gluconeogenesis remains to be analyzed in the future.
Collectively, the data described above, together with the
observation that metformin inhibits SHIP2 in vitro and in
vivo, support the idea that metformin improves insulin
sensitivity and facilitates glucose uptake in peripheral
tissues by reducing SHIP2 activity.
In search for the mechanism by which metformin en-
hances glucose uptake, we analyzed the activation of both
the PI3K/Akt andAMPK signaling pathways.Metformin
did not activate Akt in any cell or tissue type in basal
conditions (but restored SHIP2 overexpression-induced
reduction in Akt activation). Metformin activated AMPK
in vitro and showed a trend to be activated in vivo in liver,
reflecting literature revealing both AMPK-dependent and
-independentmechanisms of action formetformin (27, 32,
36). Furthermore, we found that AICAR failed to increase
glucose uptake in podocytes, indicating that although
metformin activates AMPK in cultured cells, this appears
to make a relatively small contribution toward the overall
increase in metformin-stimulated glucose uptake. Met-
formin may also signal via pathways that regulate the
traffickingofGLUTs, as it affects the configuration and/or
interactionof proteins at thePM, including themembrane-
inserted GLUTs (37), without altering total GLUT1 and
GLUT4 content (38). Indeed, we found that metformin
increases GLUT4 at the PM and verified that metformin
slows down GLUT4 endocytosis, whereas insulin does
not, aspreviously observed (29, 39). Thismaybe a result of
the altered balance of phosphoinositides at the PM, as an
increased level of PI(4,5)P2, also a substrate of SHIP2 (40)
and expected to increase upon SHIP2 inhibition, reduces
endocytosis of GLUT4 in adipocytes (41).
Insulin resistance andpodocyte apoptosis contribute to
the development of renal damage (42). Furthermore, a
recent studyproposingnovel subgroupingofdiabetes into
5 clusters reveals that individuals with severe insulin re-
sistance have a high risk to develop DKD (43). We pre-
viously found that SHIP2 overexpression suppresses the
Akt prosurvival signaling pathway and enhances podo-
cyte apoptosis (10), and thus, upregulation of SHIP2 ex-
pression or activity might contribute to insulin resistance
and loss of podocytes in DKD. Notably, we observed that
SHIP2 activity is elevated in kidneys of patients with T2D
receiving nonmetformin medication compared with peo-
ple without diabetes and that metformin reduces the ele-
vated activity of SHIP2 in the kidneys of patients with
T2D, proposing a mechanism via which metformin acts
renoprotectively. Furthermore, our in vitrodata reveal that
SHIP2 overexpression reduces insulin-induced Akt acti-
vation and that metformin restores the reduced Akt ac-
tivity back to normal and protects podocytes from SHIP2
overexpression-induced apoptosis. Supporting this, we
observed that podocyte losswas attenuated inmetformin-
treatedT2Dpatients. This is corroboratedby recent studies
showing thatmetformin prevents renal podocyte injury in
a rat model of T2D by repressing oxidative stress, reduces
high-glucose-induced apoptosis in cultured podocytes via
activationofAMPKand inhibitionofmammalian target of
rapamycin, and decreases albuminuria in patients with
T2D (44–47). Podocyte apoptosis is an early glomerular
phenotype that coincides with the onset of albuminuria
and is associated with progressive podocyte depletion in
DKD (15). We propose that metformin could prevent the
progression of DKD at an early stage by ameliorating in-
sulin resistance and preventing podocyte loss via in-
hibition of SHIP2 activity. This accords with Ahlqvist et al
(43), noting that the proportion of patients with severe
insulin resistance receiving metformin was low, even
though this subgroup would be expected to benefit the
most from metformin treatment. The finding that metfor-
min acts on its direct cellular target, SHIP2, in human
kidney tissue in vivo is a significant finding, as the in-
hibitory effect of metformin on mtGPD still awaits for
confirmation in human liver.
Inhibitors identified in virtual screening included
Food and Drug Administration-approved drugs used
to treat cardiovascular disease, certain types of cancer,
autoimmunediseases, anorexia, cachexia, andweight loss
associated with cancer and AIDS (1, 48–50). Emerging
evidence indicates that in addition to regulating insulin
signaling, cytoskeleton remodeling, and receptor endo-
cytosis (51), SHIP2 is implicated in the development and
progression of certain types of cancer (52). This, together
withour in silicodata, confirms the importanceof SHIP2as
a drug target for diabetes and specific types of cancer.
In summary, we show thatmetformin binds directly to
the phosphatase domain of SHIP2 and reduces its activity
in vitro and in vivo. Furthermore, podocyte loss was de-
creased in the kidneys of patients with T2D receiving
metformin, suggesting a novel mechanism for the reno-
protectiveeffects ofmetformin. Thus, our findingsunravel
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a novel molecular mechanism by which metformin
enhances glucose transport and protects against podo-
cyte loss.
ACKNOWLEDGMENTS
The authors thank M. Saleem (Southmead Hospital, Univer-
sity of Bristol, Bristol United Kingdom) for kindly providing
immortalized human podocytes, S. Cushman (National Institutes
of Health, Bethesda, MD, USA) for the HA-GLUT4-GFP
construct, and C. A. Mitchell (Monash University, Clayton, VIC,
Australia) and G. Krystal (Terry Fox Laboratory, Vancouver, BC,
Canada) for human SHIP2 (NP_001558) and SHIP1 (NP_
005532) cDNA constructs, respectively. Leena Saikko, High
Throughput Biomedicine Unit, Biomedicum Flow Cytometry
Unit, Biochemical Analysis Core for Experimental Research,
and Genome Biology Unit (University of Helsinki) are acknowl-
edged for excellent technical assistance. This work was supported
by the European Research Council (Grant 242820; to S.L.),
Academy of Finland (Grants 131255, 218021, and 255551 to S.L.;
Grant 134379 to P.-H.G.), Jane and Aatos Erkko Foundation (to
S.L.), European Foundation for the Study of Diabetes/
Boehringer Ingelheim Research Programme (to S.L.), Sigrid
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